Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 413

1.

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.

Cell Death Dis. 2013 Sep 26;4:e814. doi: 10.1038/cddis.2013.312.

2.

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.

Park IH, Kim JY, Jung JI, Han JY.

Invest New Drugs. 2010 Dec;28(6):791-9. doi: 10.1007/s10637-009-9319-4. Epub 2009 Sep 17.

PMID:
19760159
3.

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.

Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.

Int J Cancer. 2014 Jun 1;134(11):2560-71. doi: 10.1002/ijc.28594. Epub 2013 Dec 13.

4.

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.

Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.

J Exp Clin Cancer Res. 2014 Jun 17;33:52. doi: 10.1186/1756-9966-33-52.

5.

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.

Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.

6.

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.

Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.

Adv Med Sci. 2011;56(2):275-84. doi: 10.2478/v10039-011-0043-x.

PMID:
22037177
7.

Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.

Yang J, Qin G, Luo M, Chen J, Zhang Q, Li L, Pan L, Qin S.

Cell Death Dis. 2015 Jul 23;6:e1829. doi: 10.1038/cddis.2015.197.

8.

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.

Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.

Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.

PMID:
25342139
9.

Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.

Chen J, Lan T, Hou J, Zhang J, An Y, Tie L, Pan Y, Liu J, Li X.

Int J Biochem Cell Biol. 2012 May;44(5):759-69. doi: 10.1016/j.biocel.2012.01.015. Epub 2012 Jan 25.

PMID:
22305890
10.

Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.

Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP.

Anticancer Drugs. 2015 Apr;26(4):371-8. doi: 10.1097/CAD.0000000000000196.

PMID:
25514114
11.

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N.

Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10.

12.

Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.

Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.

Mol Cancer Ther. 2010 Jun;9(6):1647-56. doi: 10.1158/1535-7163.MCT-09-1009. Epub 2010 Jun 8.

13.

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.

Cancer Res. 2009 Aug 15;69(16):6515-21. doi: 10.1158/0008-5472.CAN-09-1076. Epub 2009 Jul 28.

14.

Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.

Han SY, Zhao MB, Zhuang GB, Li PP.

Lung Cancer. 2012 Jan;75(1):30-7. doi: 10.1016/j.lungcan.2011.06.001. Epub 2011 Jul 16.

PMID:
21757251
15.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.

Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538.

16.

The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.

Wang J, Wei H, Zhao B, Li M, Lv W, Lv L, Song B, Lv S.

J Mol Histol. 2014 Dec;45(6):641-52. doi: 10.1007/s10735-014-9583-2. Epub 2014 Jul 10.

PMID:
25008024
17.

Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.

Li ZX, Qu LY, Wen H, Zhong HS, Xu K, Qiu XS, Wang EH.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):7304-11. eCollection 2014.

18.

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.

Jiang Y, Yuan Q, Fang Q.

J Cancer Res Clin Oncol. 2014 Jul;140(7):1087-95. doi: 10.1007/s00432-014-1671-x. Epub 2014 Apr 13.

PMID:
24728492
19.

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.

J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11.

PMID:
21398618
20.

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.

Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.

PLoS One. 2012;7(2):e30427. doi: 10.1371/journal.pone.0030427. Epub 2012 Feb 17.

Supplemental Content

Support Center